Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Business Wire • Jul 13, 2026

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.

Seeking Alpha • Jul 4, 2026

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Jun 29, 2026

Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

ETF Trends • Jun 25, 2026

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

Zacks Investment Research • Jun 17, 2026

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

Zacks Investment Research • Jun 15, 2026

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.

Business Wire • Jun 14, 2026

Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026.

Business Wire • Jun 4, 2026

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.

Business Wire • May 30, 2026